NOVARTIS AG Patent applications |
Patent application number | Title | Published |
20160137730 | ANTIBODY DRUG CONJUGATES - This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents. | 05-19-2016 |
20160136175 | COMBINATION OF A PHOSPHATIDYLINOSITOL-3-KINASE (PI3K) INHIBITOR AND A MTOR INHIBITOR - The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound of formula (I) and (b) a mTOR inhibitor for the treatment of a target of rapamycin (mTOR) kinase dependent disease, especially a cancer disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human. | 05-19-2016 |
20160136171 | Combination Therapy Comprising A CDK4/6 Inhibitor and a PI3K Inhibitor for Use in the Treatment of Cancer - A combination of a CDK4/6 inhibitor and a P3Kinase inhibitor for the treatment of cancer. | 05-19-2016 |
20160136150 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK - The present invention relates to compounds of formula I: | 05-19-2016 |
20160130280 | ALKYLATION WITH AN ALKYL FLUOROALKYL SULFONATE - The present invention discloses a process for preparing a chemical compound comprising reacting a nucleophile with an alkyl fluoroalkyl sulfonate in the presence of a base of formula NR1R2R3, wherein R1 and R2 are independently 2-methyipropyl or isopropyl and R3 is —CH(R4)(R5), wherein R4 and R5 are identical or different alkyls that are optionally connected to form a ring. The invention also relates to a process for preparing an alkyl fluoroalkyl sulfonate. The invention further relates to a use of the base in a chemical reaction comprising an alkyl fluoroalkyl sulfonate. The process and uses are suitable for preparing chemical compounds, reactants or intermediates thereof, and in particular for preparing API or reactants, like for example everolimus or reactants for its preparation. | 05-12-2016 |
20160129003 | Pharmaceutical Combinations - A pharmaceutical combination comprising: (a) a phosphatidylinositol-3-kinase inhibitor selected from 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile, 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine, (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or any pharmaceutically acceptable salt thereof, and (b) an anaplastic lymphoma kinase inhibitor, particularly for use in the treatment or prevention of a proliferative disease; uses of such a combination in the treatment or prevention of proliferative diseases; to pharmaceutical compositions of the combination of said therapeutic agents and methods of treating a proliferative disease in a subject comprising administering to said subject a therapeutically effective amount of such a combination. | 05-12-2016 |
20160128937 | CIRCULATION OF COMPONENTS DURING MICROFLUIDIZATION AND/OR HOMOGENIZATION OF EMULSIONS - An improved method for the manufacture of an oil-in-water emulsion involves circulation of emulsion components between a first container and a second container via a homogenizer and/or via a microfluidization device. Usefully, all of the emulsion components from the first container are emptied before being returned. | 05-12-2016 |
20160122726 | INFLUENZA VIRUS REASSORTMENT - The invention provides reassortant influenza strains. | 05-05-2016 |
20160120935 | Sustanined Release Formulation Comprising Octreotide and Two or More Polyactide-co-glycolide Polymers - The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-co-glycolide polymers (PLGAs). | 05-05-2016 |
20160120871 | PHARMACEUTICAL COMBINATIONS OF A PI3K INHIBITOR AND A MICROTUBULE DESTABILIZING AGENT - The present invention relates to a combination comprising (a) a phosphatidylinositol 3-kinase inhibitor selected from 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine, (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or a pharmaceutically acceptable salts thereof, and (b) a microtubule destabilizing agent for simultaneous, separate or sequential use for the treatment of a tumor disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a tumor disease comprising administration of said combination to a subject in need thereof; use of such combination for preparation of a medicament for the treatment of a tumor disease; and a commercial package thereto. | 05-05-2016 |
20160115156 | PYRIMIDIN-4-YL)OXY)-1H-INDOLE-1-CARBOXAMIDE DERIVATIVES AND USE THEREOF - This invention relates to certain metabolites of N-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6-((methyl-amino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide In particular, the present invention relates to pharmaceutical compositions comprising these metabolites, as well as processes for their preparation and their use in the treatment of diseases. | 04-28-2016 |
20160113870 | CIRCULATION OF COMPONENTS DURING MICROFLUIDIZATION AND/OR HOMOGENIZATION OF EMULSIONS - An improved method for the manufacture of an oil-in-water emulsion involves circulation of emulsion components between a first container and a second container via a homogenizer and/or via a microfluidization device. Usefully, all of the emulsion components from the first container are emptied before being returned. | 04-28-2016 |
20160108110 | ANGIOPOETIN-LIKE 4 (ANGPTL4) ANTIBODIES AND METHODS OF USE - The present invention relates to monoclonal antibodies binding to human angiopoetin-like protein 4 (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same. | 04-21-2016 |
20160108091 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE - The invention provides a cyclic polypeptide of Formula I (SEQ ID NO: 1): | 04-21-2016 |
20160108051 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASE - The invention provides a class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent malaria. | 04-21-2016 |
20160108047 | IMIDAZOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE - The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. | 04-21-2016 |
20160108025 | POLYCYCLIC HERG ACTIVATORS - The present invention provides a compound of formula I, in which R | 04-21-2016 |
20160108012 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION - Prostaglandin conjugates and derivatives and methods for their use to treat glaucoma and/or lower intraocular pressure are disclosed. Additionally, ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma and elevated intraocular pressure are disclosed. Such compositions comprise an effective amount of prostaglandin conjugates or derivatives of the present invention. | 04-21-2016 |
20160106753 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives - The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, | 04-21-2016 |
20160102107 | PYRAZOLO-PYRROLIDIN-4-ONE DERIVATIVES AS BET INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE - The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. | 04-14-2016 |
20160102092 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors - The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; | 04-14-2016 |
20160102062 | N-Oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1--1-methyl-urea - An N-oxide of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea, pharmaceutically acceptable salts thereof, compositions including the compound and its pharmaceutically acceptable salts, and methods of preparing the compound and the compositions (such as, for example, by oxidizing 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea with an oxidizing agent) are described. Further described herein are methods of using the compound and compositions of the present technology, alone and in combination with other suitable agents, to treat various diseases, including but not limited to, those that can be prevented, inhibited or ameliorated by inhibition of kinase activity selected from FGFR1, FGFR2, FGFR3 or FGFR4. | 04-14-2016 |
20160101167 | Composition of Organic Compounds - The present invention relates to compositions comprising a construct comprising the Aβ1-6 peptide and a pharmaceutically acceptable adjuvant, for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type. | 04-14-2016 |
20160101146 | TREATMENT FOR INFECTION WITH HEPATITIS B VIRUS ALONE OR IN COMBINATION WITH HEPATITIS DELTA VIRUS AND ASSOCIATED LIVER DISEASES - The invention concerns the use of cyclophilin inhibitors in the treatment of Hepatitis B and Hepatitis D virus infections. | 04-14-2016 |
20160101097 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists - A medicament comprising, separately or together (A) glycopyrrolate; and | 04-14-2016 |
20160097061 | VIRAL VECTORS FOR THE TREATMENT OF RETINAL DYSTROPHY - The present invention relates to viral vectors that are capable of delivering a heterologous gene to the retina and in particular delivering RLBP1 to RPE and Müller cells of the retina. The invention also relates nucleic acids useful for producing viral vectors, compositions comprising the viral vectors and uses of the compositions and viral vectors. The invention also relates to methods of delivering and/or expressing a heterologous gene to the retina, improving the rate of dark adaption in a subject and treating RLBP1-associated retinal dystrophy. | 04-07-2016 |
20160096843 | PYRAZOLO-PYRROLIDIN-4-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE - The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the pyrazolo-pyrrolidin-4-one derivatives, and their use as BET inhibitors for the treatment of conditions or diseases such as cancer. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. | 04-07-2016 |
20160095927 | Ophthalmic Compositions Containing A Synergistic Combination of Two Polymers - Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity. | 04-07-2016 |
20160095843 | PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE - The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. | 04-07-2016 |
20160089336 | Octreotide depot formulation with constantly high exposure levels - The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs). | 03-31-2016 |
20160082014 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS - The present invention relates to methods for modulating the Wnt signaling pathway using compounds of Formula (1), | 03-24-2016 |
20160081934 | Compositions of Glycopyrronium Salt for Inhalation - A process for preparing dry powder formulations of a glycopyrronium salt for inhalation that have good stability. The process involves (a) micronising a glycopyrronium salt together with an anti-adherent agent, and (b) admixing carrier particles to form the dry powder formulation. | 03-24-2016 |
20160075727 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS - The present invention provides a compound of Formula I: | 03-17-2016 |
20160075670 | BENZOTHIAZOLONE COMPOUND - The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form | 03-17-2016 |
20160068546 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES - A compound of Formula I | 03-10-2016 |
20160058878 | Process for preparing a composition of pegylated proteins - This invention is in the field of protein pegylation. In particular, it relates to a method for pegylating therapeutic proteins. The invention also relates to the use of such pegylated therapeutic polypeptides for treating muscle diseases and disorders. | 03-03-2016 |
20160051667 | CONJUGATION OF STAPHYLOCOCCUS AUREUS TYPE 8 CAPSULAR POLYSACCHARIDES - The invention provides a process for preparing a conjugate of a | 02-25-2016 |
20160051551 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS - A pharmaceutical formulation comprising the compound of formula | 02-25-2016 |
20160051523 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS - This invention pertains generally to antibacterial compounds of Formula I, | 02-25-2016 |
20160046724 | TREATMENT OF CANCER USING HUMANIZED ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR - The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain. | 02-18-2016 |
20160046711 | ANTI-CDH6 ANTIBODY DRUG CONJUGATES - The present invention relates to anti-CDH6 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer. | 02-18-2016 |
20160046710 | NOTCH2 BINDING MOLECULES FOR TREATING RESPIRATORY DISEASES - The balance and distribution of epithelial cell types is required to maintain tissue homeostasis. In the lung, perturbations of this balance are hallmarks of human respiratory diseases, including goblet cell metaplasia and enhanced mucus secretion in asthma and chronic obstructive pulmonary disease. We found that inflammatory cytokine treatment resulted in a skewing of basal cell differentiation towards a goblet cell fate, culminating in enhanced mucus production. We identified Notch2 as a key node required for cytokine-induced goblet cell metaplasia in vitro and in vivo Inhibition of Notch2 prevents goblet cell metaplasia induced by a broad range of stimuli, which is a hallmark of many respiratory diseases. | 02-18-2016 |
20160046605 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE - PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity. | 02-18-2016 |
20160046573 | IDENTIFYING PATIENT RESPONSE TO S1P RECEPTOR MODULATOR ADMINISTRATION - The invention provides a method of assessing the appropriate therapeutic dose of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid to administer to a patient in need thereof. It is determined whether a patient has a particular metabolizer genotype. If the patient does not have a particular genotype, 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof is administered at a standard dose. If the patient has the poor metaboliser genotype, either 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, is administered at a dose below that of the standard therapeutic dose; or is not dosed at all. | 02-18-2016 |
20160045513 | ISOXAZOLE COMPOUND FOR THE TREATMENT OF CANCER - The use of 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide or a tautomer thereof or a pharmaceutically acceptable salt or a hydrate or a solvate for the treatment of cancer of the bladder, the colon, the liver, the lung, the breast, the vagina, the ovaries, the pancreas, the kidney, the stomach, the gastrointestinal tract, the prostate, the head and neck, the peritoneal cavity, the thyroid, the bone, the brain, the central nervous system and/or the blood and/or for the treatment of myelodysplastic syndrome, systemic mastocytosis, von Hippel-Lindau syndrome, multicentric Castleman disease and/or psioriasis. | 02-18-2016 |
20160045505 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES - The present invention provides compounds of formula (I): (Formula (I)) or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease. | 02-18-2016 |
20160045501 | Method of Optimizing the treatment of Proliferative Diseases Mediated by the Tyrosine Kinase Receptor KIT with Imatinib - The invention relates to a method of treating proliferative diseases mediated by the tyrosine kinase receptor KIT, in particular GIST, in a human patient population. | 02-18-2016 |
20160045441 | Pharmaceutical Compositions Comprising Everolimus - The invention relates to a pharmaceutical formulation comprising 40-O-(2-hydroxy)ethyl-rapamycin in a high drug load part and an immediate release part. In addition, the invention relates to a formulation comprising 40-O-(2-hydroxyethyl-rapamycin in a first layer and a surfactant in a layer beneath the first layer. The pharmaceutical composition is particularly suitable for use as a medicament. | 02-18-2016 |
20160039928 | Anti-IL-17A antibodies and their use in treating autoimmune and inflammatory - The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17 A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17 A antagonists (inhibit the activities of IL-17 A and IL-17 AF) and are capable of inhibiting IL-17 A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL 17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders. | 02-11-2016 |
20160039832 | SALT(S) OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO- [2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF - This invention relates to (1) process of making 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and salt(s) thereof; (2) novel salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-carboxylic acid dimethylamide; (3) pharmaceutical compositions comprising the same; and (4) methods of treatment using the same. | 02-11-2016 |
20160039802 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH - The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R | 02-11-2016 |
20160038585 | INFLUENZA VIRUS REASSORTMENT - New influenza donor strains for the production of reassortant influenza B viruses are provided. | 02-11-2016 |
20160038504 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS - The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent. | 02-11-2016 |
20160032402 | BIOMARKERS ASSOCIATED WITH BRM INHIBITION - The invention provides methods of detecting cancer biomarkers, such as one or more SWI/SNF complex mutations, in order to determine a cancer subject's amenability to therapeutic treatment with a BRM inhibitor. Kits, methods of screening for candidate BRM inhibitors, and associated methods of treatment are also provided. | 02-04-2016 |
20160032321 | METHODS OF NUCLEASE-BASED GENETIC ENGINEERING - The present invention relates to genetic techniques employing the direct ligatation of an external DNA fragment generated in situ by the same ZFNs that target the genome. ObLiGaRe, i.e., the obligated ligation-gated recombination, is a new method for genetic engineering using custom designed nucleases, and a strategy of site-specific gene insertion utilizing the NHEJ pathway. It applies a similar logic to the one used in unidirectional loxP sites(Oberdoerffer et al., 2003) but maintains all the advantages and flexibility of CDNs. | 02-04-2016 |
20160031975 | Compositions and Methods for Antibodies Targeting Complement Protein C5 - The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof. | 02-04-2016 |
20160031961 | METHODS AND COMPOSITIONS USING KLOTO-FGF FUSION POLYPEPTIDES - The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. In one embodiment, the fusion polypeptide comprises a Klotho polypeptide, a FGF (such as FGF23) and (optionally) a modified Fc fragment. The Fc fragment can, for example, have decreased binding to Fc-gamma-receptor and increased serum half-life. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23) and a modified Fc fragment. | 02-04-2016 |
20160031836 | BIOMARKER - The invention is directed, in part, to selective cancer treatment regimes based on assaying for the presence or absence of a mutation in a nucleic acid that encodes MLL1 or for the presence of reduced levels of MLL1. | 02-04-2016 |
20160031822 | 3'-[(2Z)-[1-(3,4-DIMETHYLPHENYL)-1,5-DIHYDRO-3-METHYL-5-OXO-4H-PYRAZOL-4-Y- LIDENE]HYDRAZINO]-2'-HYDROXY-[1,1'-BIPHENYL]-3-CARBOXYLIC ACID BIS-(MONOETHANOLAMINE) - Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same. | 02-04-2016 |
20160030585 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES - The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: | 02-04-2016 |
20160030572 | LIQUID FORMULATIONS - Disclosed is a concentrate for dilution comprising a S1P receptor agonist or a pharmaceutically acceptable salt thereof, propylene glycol and optionally glycerin. This formulation is adapted for patients in a difficult condition to swallow. | 02-04-2016 |
20160024525 | REVERSE GENETICS USING NON-ENDOGENOUS POL I PROMOTERS - Expression of a transgene is driven in a host cell using a pol I promoter which is not endogenous to an organism from the same taxonomic order from which the host cell is derived. | 01-28-2016 |
20160024079 | Complement Factor B inhibitors and uses there of - The present invention provides a compound of formula (I): wherein X is N or CH, Y is NH, O or S, methods for manufacturing these compounds, and their uses as Factor B inhibitors for the treatment of conditions and diseases associated with complement alternative pathway activation such as age-related macular degeneration, diabetic retinopathy and related ophthalmic diseases. The present invention further provides pharmaceutical compositions and combinations of pharmacologically active agents. | 01-28-2016 |
20160015815 | PHENYLEPHRINE FORMULATIONS WITH IMPROVED STABILITY - A pharmaceutical composition includes a pharmaceutical polysaccharide and phenylephrine hydrochloride. The ratio of said polysaccharide to phenylephrine hydrochloride is sufficient to dilute the composition such that phenylephrine hydrochloride is stable at high temperature and humidity. | 01-21-2016 |
20160002727 | NOVEL ANDROGEN RECEPTOR MUTATION - Compositions and methods are provided for diagnosis, prognosis and treatment of AR-related diseases, such as prostate diseases, such as prostate cancer, breast cancer, and many other diseases. In particular, a novel and clinically relevant mutation at position 876 of the androgen receptor (AR) has been identified. Drug sensitivity can be predicted and therapeutic regimens can be planned on the basis of the presence or absence of this mutation. Polypeptides comprising, antibodies to, and polynucleotides encoding the mutant AR can be used to identity novel treatments. A double mutation in AR at positions 741 and 877 is also shown to be useful for patient stratification. | 01-07-2016 |
20160002328 | Methods of Treating Kawasaki Disease using IL-1beta Antibodies - This invention relates to a novel use of IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans. | 01-07-2016 |
20160000761 | Formulation comprising benzothiazolone compound - The present invention relates to a pharmaceutical composition in solid oral dosage form comprising (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one acetate salt. | 01-07-2016 |
20150376183 | IP Receptor Agonist Heterocyclic Compounds - The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. | 12-31-2015 |
20150374807 | Amyloid beta1-6 Antigen Arrays - The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an Aβ1-peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one Aβ1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer's disease and as a pharmaccine to prevent or cure Alzheimer's disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune, responses within the indicated context. | 12-31-2015 |
20150374726 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS - The present invention provides a compound of formula I; | 12-31-2015 |
20150366868 | CANCER TREATMENT METHOD - A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolineamines. | 12-24-2015 |
20150366856 | COMPOUNDS AND METHODS FOR MODULATING FXR - The present invention relates to compounds of Formula (I), | 12-24-2015 |
20150361065 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS - The present invention relates to compounds of formula I: in which n, m, X, Y | 12-17-2015 |
20150359624 | LENS DELIVERY SYSTEM - An intraocular lens delivery system includes an injector body having a bore surrounded by an inner wall. The system further includes a plunger configured to fit within the bore. The system also includes a plurality of deflectable members connected to the plunger and configured to contact the inner wall and to be deflected when the plunger is inserted within the bore. The deflectable members center the shaft and, when inserted within the injector body, contribute to producing a predetermined force resisting advancement of the plunger when deflected in the bore. | 12-17-2015 |
20150354006 | MARKERS FOR ACUTE LYMPHOBLASTIC LEUKEMIA - The invention provides methods of detecting a NSD2 mutation in a cancer cell, methods cancer diagnosis and methods of screening for NSD2 inhibitors. | 12-10-2015 |
20150353935 | MELK Regulation for the Treatment of Breast Cancer - Methods for inhibiting growth or proliferation of breast cancer cells are provided. The methods include administering to a subject in need thereof in an amount that is effective to inhibit growth or proliferation of the breast cancer cells a MELK inhibitor, wherein the breast cancer cells are estrogen receptor (ER) negative. In some aspects, the methods include administering to a subject in need thereof in an amount that is effective to inhibit growth or proliferation of the breast cancer cells a MELK inhibitor, a FoxM1 inhibitor or a MELK inhibitor and a FoxM1 inhibitor, wherein the breast cancer cells are estrogen receptor (ER) negative. Methods of treatment for breast cancer and methods of identifying patients having cancer that are likely to benefit from treatment with a MELK inhibitor, a FoxM1 inhibitor or a MELK inhibitor and a FoxM1 inhibitor are also provided. | 12-10-2015 |
20150353900 | INFLUENZA VIRUS REASSORTMENT - Improved methods for the production of reassortant influenza viruses are provided. | 12-10-2015 |
20150353551 | SUBSTITUTED PURINONE COMPOUNDS - The invention relates to compounds of formula (I): (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of as MDM2 and/or MDM4, and combinations comprising such compounds. | 12-10-2015 |
20150344479 | NOVEL HETEROCYCLIC DERIVATIVES - The invention relates to novel heterocyclic compounds of the formula | 12-03-2015 |
20150344476 | Naphthyridinedione derivatives - The invention relates to compound of the formula (I′) | 12-03-2015 |
20150344471 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES - The present invention provides compounds of formula I: | 12-03-2015 |
20150342951 | Use of Inhibitors of the Activity or Function of PI3K - The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject. | 12-03-2015 |
20150336986 | TRICYCLIC COMPOUNDS FOR INHIBITING THE CFTR CHANNEL - The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. | 11-26-2015 |
20150336960 | ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS - The present invention provides a compound of formula (I) as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula (I), and pharmaceutical compositions comprising such compounds. | 11-26-2015 |
20150336914 | BENZOTHIAZOLONE COMPOUND - The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form | 11-26-2015 |
20150335646 | Pyrimido[4,5-b]quinoline-4,5(3H,10H)-diones - The invention relates to compound of the formula (I); or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it. | 11-26-2015 |
20150335483 | ULTRASONIC HAND PIECE - A surgical hand piece comprises a generally cylindrical horn with a flange on one end. The flange has a central hub and first and second protruding sections. First and second polarized piezoelectric crystals are held against the flange such that rotative or torsional motion is induced in the horn. | 11-26-2015 |
20150329614 | STABILIZED INSULIN-LIKE GROWTH FACTOR POLYPEPTIDES - This invention is in the field of IGF-1 modifications. In particular, it relates to modified IGF-polypeptides and modified IGF-1 precursor polypeptides wherein the cleavage of E-peptide is prevented. The invention also relates to the use of such polypeptides for treating muscle diseases and disorders. | 11-19-2015 |
20150329554 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS - The present invention provides compounds of formula I: | 11-19-2015 |
20150329549 | CARBOXAMIDE DERIVATIVES - The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt or co-crystal thereof; | 11-19-2015 |
20150329529 | CARBOXAMIDE DERIVATIVES - The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; | 11-19-2015 |
20150327760 | IMAGING PROBES AND ASSOCIATED DEVICES, SYSTEMS, AND METHODS UTILIZING SPEAKER ACTUATORS - Devices, systems, and methods that utilize a speaker to impart motion to an optical fiber positioned within an imaging probe are provided. In some embodiments, an ophthalmic imaging apparatus comprises an optical probe having a handle sized and shaped for handheld grasping by a user; and a cannula coupled to the handle, the cannula sized and shaped for insertion into an eye to be treated; an optical fiber positioned at least partially within the optical probe, the optical fiber configured to receive an imaging light from an imaging light source and guide the imaging light to an optical element positioned within the cannula of the optical probe; and an actuator system configured to impart motion to the optical fiber, the actuator system including a speaker positioned within the optical probe. | 11-19-2015 |
20150327759 | IMAGING PROBES AND ASSOCIATED DEVICES, SYSTEMS, AND METHODS UTILIZING LEVER ARM ACTUATORS - Devices, systems, and methods that utilize a mechanical structure, such as a lever arm or a flexure mechanism, and an electrically energizable member, such as an actuator, to impart motion to an optical fiber positioned within an imaging probe are provided. In some embodiments, an ophthalmic imaging probe can include a handle; a cannula coupled to the handle; an optical fiber positioned at least partially within the handle and the cannula, the optical fiber configured to receive an imaging light from an imaging light source and guide the imaging light to an optical element positioned within a distal portion of the cannula; and an actuator system configured to impart motion to the optical fiber, the actuator system including a mechanical structure and an electrically energizable member configured to selectively impart motion to the mechanical structure upon the electrically energizable member being electrically energized. | 11-19-2015 |
20150323548 | METHODS OF MONITORING THE MODULATION OF THE KINASE ACTIVITY OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USES OF SAID METHODS - The present invention relates generally to methods of in vitro diagnostics, in particular the use of a compound selected from the group consisting of fibroblast growth factor 23 (FGF23), inorganic phosphorus (P), the product of inorganic phosphorus and total calcium (P×tCa), osteopontin (OPN) and parathyroid hormone (PTH) as biomarker. Said biomarkers can be used to monitor the modulation of fibroblast growth factor receptor (FGFR) kinase activity, in particular its inhibition, and/or the occurrence of secondary effects of FGFR inhibition. The invention further provides methods and kits relating to these uses. | 11-12-2015 |
20150322528 | BIOMARKERS ASSOCIATED WITH CDK INHIBITORS - The invention provides methods of monitoring differential gene expression of biomarkers to determine patient sensitivity to Cyclin Dependent kinase inhibitors (CDKi), methods of determining the sensitivity of a cell to a CDKi, methods of treating a patient with a CDKi and methods of screening for candidate CDKi. | 11-12-2015 |
20150322148 | Methods of Using IL-1beta Compounds - This invention relates to methods employing IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules as described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans. | 11-12-2015 |
20150322131 | PRODUCTION OF THERAPEUTIC PROTEINS IN GENETICALLY MODIFIED MAMMALIAN CELLS - The invention relates to methods for the production of therapeutic proteins in mammalian cells. In one embodiment, the method comprises producing a therapeutic protein such as IGF-1 in a mammalian cell endogenously expressing a cognate receptor of said recombinant therapeutic protein and wherein binding of said therapeutic protein to said cognate receptor results in a low titer of the therapeutic protein, the method comprising with a mammalian cell being deficient in the expression of the cognate receptor of said therapeutic protein and being transformed with an expression vector comprising a nucleic acid molecule encoding the therapeutic protein: a. Cultivating said cell under conditions allowing the expression of the therapeutic protein; and b. Harvesting the therapeutic protein from the mammalian cell cultivated in step a, wherein said mammalian cell produces at least 1.5 fold more therapeutic protein than a cell in which the expression of the cognate receptor has not been so modified. | 11-12-2015 |
20150322060 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS - The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as a factor D inhibitor for the treatment of ophthalmic diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. | 11-12-2015 |
20150322038 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS - The invention relates to novel heterocyclic compounds of the formula | 11-12-2015 |
20150320880 | ANTIBODY DRUG CONJUGATES - The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer. | 11-12-2015 |
20150320687 | PHARMACEUTICAL COMPOSITIONS CONTAINING A DGAT1 INHIBITOR - The present invention relates to a pharmaceutical composition comprising
| 11-12-2015 |
20150320593 | EQUIPMENT AND METHODS USED IN FOLDING AND IMPLANTING FOLDABLE LENSES IN THE EYE - Apparatuses, systems, and methods for folding an intraocular lens and inserting an intraocular lens into an eye are disclosed herein. In some instances, a system for folding an intraocular lens may include a folding pin, a guide pin rotatable about a longitudinal axis of the folding pin, and a stage laterally moveable relative to the folding pin. An intraocular lens may be secured between the folding pin and the guide pin and be folded onto the folding pin during rotation of the guide pin. A retention member may be used to hold the folded intraocular lens onto the folding pin. | 11-12-2015 |
20150320307 | IMAGING PROBES AND ASSOCIATED DEVICES, SYSTEMS, AND METHODS UTILIZING ELECTROSTATIC ACTUATORS - Devices, systems, and methods that utilize at least one charged electrode to impart motion to an optical fiber positioned within an imaging probe by an electrostatic force are provided. In some embodiments, an ophthalmic imaging probe can include a handle; a cannula coupled to the handle; an optical fiber positioned at least partially within the handle and the cannula, the optical fiber configured to receive an imaging light from an imaging light source and guide the imaging light to an optical element positioned within the cannula; and an actuator system configured to impart motion to the optical fiber, the actuator system including an electrode positioned within the cannula and configured to impart motion to the optical fiber by selectively imparting an electric charge to the electrode and/or the electrically conductive layer of the optical fiber. | 11-12-2015 |
20150315150 | KINASE INHIBITORS AND METHODS OF THEIR USE - New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer. | 11-05-2015 |
20150313902 | PHARMACEUTICAL COMBINATION COMPRISING BINIMETINIB - A combination of a CDK4/6 inhibitor and a MEK inhibitor for the treatment of diseases such as cancer. | 11-05-2015 |
20150307475 | Autotaxin inhibitors - The present invention relates to novel compounds of formula (I) (I) that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in the treatment of an ATX-dependent or ATX-mediated disease or condition. | 10-29-2015 |
20150306172 | CYCLIC PEPTIDES AND USE AS MEDICINES - The present invention provides a compound of formula I; | 10-29-2015 |
20150306104 | COMBINATION THERAPY - The present invention relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is a mTOR inhibitor or a pharmaceutically acceptable salt thereof. | 10-29-2015 |
20150306085 | CSF-1R INHIBITORS FOR TREATMENT OF BRAIN TUMORS - The present invention provides a compound of formula I; | 10-29-2015 |
20150297692 | Composition Comprising the Amyloid Beta 1-6 Peptide Coupled to a Virus-Like Particle and an Adjuvant - The present invention relates to compositions comprising a construct comprising the Aβ1-6 peptide and a pharmaceutically acceptable adjuvant, for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type. | 10-22-2015 |
20150297604 | Combination Products with Tyrosine Kinase Inhibitors and their Use - The present invention relates to pharmaceutical products comprising a combination of (i) a MET inhibitor and (ii) an EGFR inhibitor, or a pharmaceutically acceptable salt thereof, respectively, or a prodrug thereof, which are jointly active in the treatment of proliferative diseases, corresponding pharmaceutical formulations, uses, methods, processes commercial packages and related invention embodiments. | 10-22-2015 |
20150291954 | ORGANIC COMPOSITIONS TO TREAT BETA-CATENIN-RELATED DISEASES - The present disclosure relates to RNAi agents useful in methods of treating Beta-Catenin-related diseases such as adenomatous polyposis of the colon, colorectal cancer, basal cell carcinoma, breast cancer, kidney cancer, Wilms tumors, medulloblastoma, ovarian cancer, adrenocortical tumors, gastric cancer, liver cancer, melanoma, pancreatic cancers, prostate cancer, renal cancer, ectopic teeth and taste papillae, skin cancer, pilomatrixoma, anaplastic thyroid carcinoma, and uterine carcinosarcoma, oligodontia, osteoporosis, ageing, degenerative diseases, bedsores, chronic wounds and impaired wound healing, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to Beta-Catenin. | 10-15-2015 |
20150291598 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES - The present invention provides compounds of formula I: [INSERT FORMULA HERE] or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease, such as malaria, caused by a | 10-15-2015 |
20150291526 | PYRIDONE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF TUBERCULOSIS - A compound of Formula (I) is provided that has been shown to be useful for treating a disease, disorder or syndrome that is mediated by the inhibition of mycolic acid biosynthesis through inhibition of | 10-15-2015 |
20150290204 | COMBINATION THERAPY - A pharmaceutical combination comprising (a) a compound of formula (I), | 10-15-2015 |
20150290009 | METHODS FOR MAKING CONJUGATES FROM DISULFIDE-CONTAINING PROTEINS - A weight loss device ( | 10-15-2015 |
20150284446 | SYNTHETIC LINEAR APELIN MIMETICS FOR THE TREATMENT OF HEART FAILURE - The invention relates to novel compositions comprising modified apelin-13 peptide sequences designed to treat cardiovascular disease in subjects to whom they are administered, and which exhibit greater resistance to degradation, and equivalent or greater bioactivity than their wild type counterparts. The invention also relates to methods of making said compositions and using said compositions as pharmaceutically active agents to treat cardiovascular disease. | 10-08-2015 |
20150283212 | ORAL CALCITONIN COMPOSITIONS AND APPLICATIONS THEREOF - The present invention relates to compositions for the oral delivery of pharmacologically active calcitonin, to methods of synergistically enhancing the biological effects of orally administered calcitonin with D type vitamins and calcium, and to methods of treating and/or preventing disease in mammals, particularly humans, by orally administering calcitonin compositions in accordance with the invention. | 10-08-2015 |
20150274733 | DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS - The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof; as further described herein. The present invention further provides pharmaceutical compositions comprising these compounds, and combinations comprising these compounds combined with or used with a therapeutic co-agent, as well as therapeutic uses of these compounds and compositions. These are useful in the treatment of diseases such as cancer that are associated with activation of ERK1 and/or ERK2, and especially for MAPK pathway dependent cancers showing resistance to Raf and/or MEK inhibitory cancer therapeutics | 10-01-2015 |
20150273070 | MODIFIED RELEASE OF 4-METHYL-3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]-N-[5-(4-METHYL-1H-IMIDA- ZOL-1-YL)-3-(TRIFLOUOROMETHYL)PHENYL] BENZAMIDE SOLUBILIZED USING ORGANIC ACIDS - Soluble pharmaceutical compositions of nilotinib or a pharmaceutically acceptable salt thereof were invented using one or more organic acids that function as a solubilizing agent, increasing the bioavailability of nilotinib and supressing the food effect associated with certain compositions of nilotinib. The pharmaceutical compositions are in the form of solid oral dosage forms, including capsules and tablets. | 10-01-2015 |
20150273015 | TREATMENTS OF HEPATITIS C VIRUS INFECTION - The invention concerns the use of cyclophilin inhibitors in the treatment of Hepatitis C virus infection. | 10-01-2015 |
20150266867 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS - This invention pertains generally to antibacterial compounds of Formula I, | 09-24-2015 |
20150265616 | Pharmaceutical Combinations Comprising a B-RAF Inhibitor, and EGFR Inhibitor and Optionally a PI3K-Alpha Inhibitor - A pharmaceutical combination comprising (a) a B-Raf inhibitor, (b) a EGFR inhibitor and, optionally, (c) a PI3K inhibitor; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination. | 09-24-2015 |
20150259675 | SHORT INTERFERING RIBONUCLEIC ACID (siRNA) FOR ORAL ADMINISTRATION - Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification. | 09-17-2015 |
20150259411 | Methods of Using Anti-IL13 Human Antibodies - The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma. | 09-17-2015 |
20150258191 | ARRANGING INTERACTION AND BACK PRESSURE CHAMBERS FOR MICROFLUIDIZATION - An improved method for the manufacture of an oil-in-water emulsion comprises using a microfluidisation device whose interaction chamber comprises a plurality of Z-type channels upstream of a back pressure chamber. | 09-17-2015 |
20150252076 | SYNTHETIC APELIN MIMETICS FOR THE TREATMENT OF HEART FAILURE - The invention provides a synthetic polypeptide of Formula I′: | 09-10-2015 |
20150250799 | Triazolopyridine Compounds - The invention relates to compounds of formula (I) and salts thereof: | 09-10-2015 |
20150250767 | Complement pathway modulators and uses thereof - The present invention provides a compound of formula I: | 09-10-2015 |
20150246881 | Processes - The invention relates to a new process for producing NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a γ-amino-δ-biphenyl-α-methylalkanoic acid, or acid ester, backbone. In detail, the new processes, according to the present invention, are ultimately related to the synthesis of intermediates to prepare the above NEP inhibitors, namely compounds according to formula (1), or salt thereof, | 09-03-2015 |
20150246110 | ADJUVANTED INFLUENZA VACCINES INCLUDING CYTOKINE-INDUCING AGENTS - While oil-in-water emulsions are excellent adjuvants for influenza vaccines, their efficacy can be improved by additionally including other immunostimulating agent(s) to improve cytokine responses, such as y-interferon response. Thus, a vaccine comprises (i) an influenza virus antigen; (ii) an oil-in-water emulsion adjuvant; and (iii) a cytokine-inducing agent. | 09-03-2015 |
20150235010 | METHOD AND SYSTEM FOR ACCESSING PATIENT DATA - Data concerning patients that have received treatment by a drug is stored and accessed to it is provided. One or more storage elements are provided that contain data concerning patients that have received the drug. The data includes data from clinical trials and data from patients prescribed the drug by a physician. A processor is programmed to search the storage elements for data on patients meeting a specified profile and to create a dataset. The dataset includes information on the patients having the specified profile, including a response of the patients to treatment using the drug. | 08-20-2015 |
20150232501 | 2'-Ethynyl Nucleoside Derivatives for Treatment of Viral Infections - The present invention provides a compound of formula A: | 08-20-2015 |
20150231226 | NOVEL ATTENUATED DENGUE VIRUS STRAINS FOR VACCINE APPLICATION - The present invention discloses a method of eliciting an immune response and a method of vaccination comprising administration of a mutated flavivirus. The mutated flavivirus comprises at least one mutation in a nucleic acid sequence encoding for the non-structural protein 5 of the flavivirus sequence resulting in inactivation of the 2′O-methyltransferase. | 08-20-2015 |
20150230984 | SYSTEMS AND METHODS FOR A MEMBRANE-FREE ELECTROLYSIS PUMP FOR AN INTRAOCULAR IMPLANT - A microfluidic pump for implantation proximate an eye of a patient is provided herein. The pump includes a first substrate portion and a second substrate portion adjacent the first and a chamber that has a bottom surface and a top surface provided by the first and second substrate portions. A gas is produced within the chamber so that it displaces fluid from the chamber. The pump also includes an inlet channel and an outlet channel coupled to the chamber, the inlet channel being separated from the chamber by a first gap and the outlet channel separated from the chamber by a second gap. The gaps inhibit the gas from moving out of the chamber. Other microfluidic pumps and intraocular devices are also disclosed. | 08-20-2015 |
20150230983 | SYSTEMS AND METHODS FOR AN ELECTROCAPILLARY PUMP FOR AN INTRAOCULAR IMPLANT - A microfluidic pump for implantation proximate an eye of a patient is disclosed herein. The microfluidic pump includes a first microfluidic actuator and a second microfluidic actuator, each with first and second chambers coupled by a channel. An electrode is in each of the first and second chambers, and the electrodes are activated to displace the first slug positioned within the channels. A flow path of the pump includes a plurality of reservoirs, one of the reservoirs being aligned with each of the first, second, third, and fourth chambers. Additionally, a flexible membrane is disposed between the flow path and the first and second microfluidic actuators. The membrane is manipulated in a manner and frequency that results in the movement of flow through the flow path. | 08-20-2015 |
20150230982 | SYSTEMS AND METHODS FOR AN ELECTROCAPILLARY POSITIVE DISPLACEMENT PUMP FOR AN INTRAOCULAR IMPLANT - A microfluidic pump for implantation proximate an eye of a patient is disclosed herein. The microfluidic pump includes a first substrate with a microfluidic actuator that includes a first chamber and a second chamber coupled by a channel, an electrode in each of the chambers, and a slug positioned within the channel. The slug is displaceable by an electric potential. The microfluidic actuator of the microfluidic pump includes a reservoir aligned with the chamber, a membrane portion separating the reservoir and the chamber, and a second reservoir aligned with the second chamber. A second membrane portion separates the second reservoir and the second chamber. Each of the reservoirs has an inlet and an outlet; each of the inlets has a valve that prevents backflow. A second substrate of the microfluidic pump includes a flow path coupling the outlet of the first reservoir to the inlet of the second reservoir. | 08-20-2015 |
20150225432 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS - The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine. | 08-13-2015 |
20150224194 | Compositions of Glycopyrronium Salt for Inhalation - A process for preparing dry powder formulations of a glycopyrronium salt for inhalation that have good stability. The process involves (a) micronising a glycopyrronium salt together with an anti-adherent agent, and (b) admixing carrier particles to form the dry powder formulation. | 08-13-2015 |
20150224185 | IMMUNOGENIC COMPOSITIONS - The invention provides an immunogenic composition comprising one or more GBS conjugates and one or more antigens selected from: a) cellular or acellular pertussis antigen, b) a tetanus toxoid, c) a diphtheria toxoid and d) an inactivated polio virus antigen, wherein each GBS conjugate is a group B | 08-13-2015 |
20150224109 | 2,3,5-Trisubstituted Thiophene Compounds and Uses Thereof - The present invention provides a compound of formula I: | 08-13-2015 |
20150218509 | CELL CULTURE MEDIUM - A cell culture medium with high content of choline chloride is provided. The cell culture media further comprise only moderate amounts of amino acids, in particular the amount of glutamine in the cell culture media is limited. The cell culture media can be used for large scale production of polypeptides using cell cultures. The cell culture media with high content of choline chloride are particularly suitable for fed-batch cell culture whereby cell viabilities stay at a higher level for a longer time and high polypeptide titers although limited amounts of amino acids are used. | 08-06-2015 |
20150218224 | Solution Phase Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates - The invention relates to a method or process for solution phase chemical manufacture of depsipeptides of the formula I, | 08-06-2015 |
20150218223 | Somatostatin Analogues - The invention provides cyclo[{4-(NH | 08-06-2015 |
20150218175 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS - The present invention provides a compound of Formula (X) or a pharmaceutically acceptable salt thereof; | 08-06-2015 |
20150218157 | Bicyclic Heteroaryl Cycloalkyldiamine Derivatives - The present invention relates to bicyclic heteroaryl cycloalkyldiamine derivatives, to processes for their production, to their use as SYK inhibitors and to pharmaceutical compositions comprising them. Formula (I) | 08-06-2015 |
20150218127 | CARBAMATE/UREA DERIVATIVES - The invention relates to compound of the formula I | 08-06-2015 |
20150216870 | Combination of PI3K Inhibitor and C-Met Inhibitor - The present invention relates to a pharmaceutical combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor or pharmaceutically acceptable salt thereof, and (b) at least one c-Met receptor tyrosine kinase inhibitor or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination. | 08-06-2015 |
20150216867 | COMPOUNDS FOR USE IN GASTRIC COMPLICATION - The present invention relates to the use of low molecular weight (lmw) compounds, especially lmw compounds with GPR4-affinity, in the treatment of diseases and disorders which includes gastroesophageal reflux disease (GERD), and/or non-erosive reflux disease (NERD) and the like. | 08-06-2015 |
20150210709 | 4-OXO-3,5,7,8-TETRAHYDRO-4H-PYRANO[4,3-D]PYRMINIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS - The present invention provides for compounds of formula (I) | 07-30-2015 |
20150210672 | ORGANIC COMPOUNDS - The present invention provides novel organic compounds of Formula (I): methods of use, and pharmaceutical compositions thereof. | 07-30-2015 |
20150209365 | Methods and Compositions for Treating Luekemia - A combination of a BCR-ABL inhibitor and a hedgehog pathway inhibitor for the treatment of leukemia. | 07-30-2015 |
20150209362 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR - A pharmaceutical combination comprising an Hsp90 inhibitor and an HER2 inhibitor, and methods of using the combination to treat proliferative disorders. | 07-30-2015 |
20150209356 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS - The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, | 07-30-2015 |
20150209291 | HIGH DRUG LOAD TABLET - The present invention pertains to a high drug load tablet comprising as active ingredient Compound I of formula | 07-30-2015 |
20150205912 | METHODS TO IDENTIFY AMINO ACID RESIDUES INVOLVED IN MACROMOLECULAR BINDING AND USES THEREFOR - The present disclosure relates to methods and computational tools based, at least in part, on computer simulations that identify hot-spot amino acid residues and binding-region amino acid residues of a protein. | 07-23-2015 |
20150203481 | Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders - The invention relates to novel heterocyclic compounds of the formula | 07-23-2015 |
20150202203 | Method of Treating Gastrointestinal Stromal Tumors - The present invention relates to a method of treating gastrointestinal stromal tumors (GIST), especially GIST, which is progressing after imatinib therapy or after imatinib and sunitinib therapy, using a combination comprising (a) a c-kit inhibitor and (b) a dual KIT inhibitor and FGFR inhibitor or FGFR inhibitor. | 07-23-2015 |
20150191462 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS - The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as complement alternative inhibitors for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. | 07-09-2015 |
20150190457 | PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS - The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as complement pathway modulators for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. | 07-09-2015 |
20150190376 | NEW INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ATRIAL ENLARGEMENT OR REMODELING - The present invention relates to the NEP inhibitor pro-drug N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid ethyl ester, or a pharmaceutically acceptable salt thereof; or the NEP inhibitor N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid, or a pharmaceutically acceptable salt thereof, pro-drug for use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling; a method for treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of the NEP inhibitor or the NEP inhibitor pro-drug, or a pharmaceutically acceptable salt pro-drug thereof, to a subject, e.g. a human subject, in need of such treatment. The present invention further relates to a pharmaceutical composition or a commercial package comprising the NEP inhibitor or the NEP inhibitor pro-drug, or a pharmaceutically acceptable salt thereof, pro-drug for use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling. | 07-09-2015 |
20150183802 | TRICYCLIC SULFONAMIDE DERIVATIVES - The invention relates to derivatives of formula (I), | 07-02-2015 |
20150183801 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 - The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers. | 07-02-2015 |
20150182525 | 4-Amino-5-Fluoro-3-[6-(4-Methylpiperazin-1-YL)-1H-Benzimidazol-2-YL]-1H-Qu- inolin-2-one for use in the Treatment of Adenoid Cystic Carcinoma - The present invention describes a method of reducing solid tumors in a subject having an adenoid cystic carcinoma comprising administering a therapeutically effective amount of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-yl]-1H-quinolin-2-one or a pharmaceutically acceptable salt thereof. | 07-02-2015 |
20150175692 | ANTI-IL-17A ANTIBODIES AND THEIR USE IN TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS - The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17A antagonists (inhibit the activities of IL-17A and IL-17AF) and are capable of inhibiting IL-17A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders. | 06-25-2015 |
20150175539 | INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF - A compound of Formula (I) is provided that has been shown to be useful for treating a disease, disorder or syndrome that is mediated by the transportation of essential molecules in the mmpL3 pathway: | 06-25-2015 |
20150174231 | COMBINATION NEISSERIAL COMPOSITIONS - Compositions comprising a first biological molecule from a | 06-25-2015 |
20150174089 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS - The present invention provides a compound of formula I′; | 06-25-2015 |
20150173622 | Forward Scanning-Optical Probes, Circular Scan Patterns, Offset Fibers - An optical light scanning probe is presented, the probe comprising a handle, shaped for grasping by a user; a cannula, protruding from a distal portion of the handle with an outer diameter smaller than 20 gauge; an optical fiber with a distal fiber-portion off a probe-axis, configured to receive a light from a light-source at a proximal fiber-portion, and to emit the received light at the distal fiber-portion; a fixed beam forming unit, disposed at a distal portion of the cannula, configured to receive the light from the distal fiber-portion, and to deflect the received light toward a target region; and a fiber actuator, housed at least partially in the handle, configured to move the distal fiber-portion to scan the deflected light along a scanning curve in the target region. | 06-25-2015 |
20150173606 | Forward Scanning Optical Probes and Associated Devices, Systems, and Methods - Devices, systems, and methods that utilize a technique of changing a position of the set of optical fibers of the fiber bundle in cooperation with the scanning of the imaging light across a proximal surface of the fiber bundle to improve the resolution of the scanned image. In particular, a bundle actuator can be provided to change a position of the set of optical fibers of the fiber bundle in cooperation with a scanning of the imaging light across the proximal surface of the fiber bundle to cover the areas of the gaps between the optical fibers and to increase a resolution of the scanned image. | 06-25-2015 |
20150173605 | Imaging Probes and Associated Devices, Systems, and Methods Utilizing an Elastomeric Optical Element - The imaging probe can comprise a housing, having a proximal region configured to be coupled to an optical cable; a cannula, extending from a distal region of the housing; an optical guide, positioned partially in the housing and partially in the cannula, configured to receive an imaging light from the cable in the proximal region of the housing, and to guide the imaging light towards a distal end of the cannula; an optical focusing element, configured to receive the imaging light from the optical guide, and to emit a focused imaging light; an elastomeric optical element, configured to receive the focused imaging light from the optical focusing element, and to be deformable to redirect the focused imaging light; and an actuator system, configured to deform the elastomeric optical element to redirect the focused imaging light. | 06-25-2015 |
20150173604 | Imaging Probes and Associated Devices, Systems, and Methods Utilizing Electroactive Polymer Actuators - Devices, systems, and methods that utilize electroactive polymer actuators to impart motion to an optical fiber positioned within an imaging probe are provided. In some embodiments, an ophthalmic imaging apparatus comprises an optical probe having a handle sized and shaped for handheld grasping by a user; and a cannula coupled to the handle, the cannula sized and shaped for insertion into an eye to be treated; an optical fiber positioned at least partially within the optical probe, the optical fiber configured to receive an imaging light from an imaging light source and guide the imaging light to an optical element positioned within the cannula of the optical probe; and an actuator system configured to impart motion to the optical fiber, the actuator system including an electroactive polymer (EAP) actuator positioned within the optical probe. | 06-25-2015 |
20150173603 | Imaging Probes and Associated Devices, Systems, and Methods Utilizing Ferrofluid-Impregnated Actuators - Devices, systems, and methods that utilize a ferrofluid-impregnated medium to impart motion to an optical fiber positioned within an imaging probe are provided. In some embodiments, an ophthalmic imaging probe can include a housing having a proximal portion and a distal portion; an optical fiber positioned within the housing, the optical fiber configured to receive an imaging light from an imaging light source and guide the imaging light to an optical element positioned within the distal portion of the housing; and an actuator system configured to impart motion to the optical fiber, the actuator system including a ferrofluid-impregnated medium (FIM) and an electrically energizable coil positioned within the housing. | 06-25-2015 |
20150159222 | MARKERS ASSOCIATED WITH HUMAN DOUBLE MINUTE 2 INHIBITORS - The invention provides methods of monitoring differential gene expression of biomarkers to determine patient sensitivity to Human Double Minute inhibitors (MDM2i), methods of determining the sensitivity of a cell to an MDM2i by measuring biomarkers and methods of screening for candidate MDM2i. | 06-11-2015 |
20150158936 | COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING FACTOR P - The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5). | 06-11-2015 |
20150152178 | IL-17 Antagonistic Antibodies - An IL-17 binding molecule, in particular .an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions or the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis. | 06-04-2015 |
20150152093 | 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH - The invention is directed to a formula (I): | 06-04-2015 |
20150152068 | NOVEL AMINO PYRIMIDINE DERIVATIVES - The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors. | 06-04-2015 |
20150150998 | METHODS FOR OXIME CONJUGATION TO KETONE-MODIFIED POLYPEPTIDES - The invention provides improved methods to prepare protein conjugates from a ketone-modified protein. In one embodiment, the protein is prepared by linking two free cysteines by reaction with a 1,3-dihaloacetone or similar ketone-containing reactant, linking the sulfur atoms of the two cysteines together. The ketone inserted between the sulfur atoms is then used to form an oxime, thus conjugating the protein to a payload. In another embodiment, two cysteine residues are tied together by reaction with a 1,3-dihaloacetone or similar reactant, and the new ketone is used to form an oxime with a suitable payload molecule, thus conjugating the protein to a payload. The method provides improved reaction conditions for the oxime formation, whereby higher yields and improved product homogeneity are achieved. | 06-04-2015 |
20150150877 | NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE - The invention relates to novel oxazine derivatives of formula (I), and pharmaceutically acceptable salts thereof, | 06-04-2015 |
20150148402 | MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS OF USE - The present invention provides double-stranded RNA molecules that mediate RNA interference in target cells, preferably hepatic cells. The invention also provides double-stranded RNA (dsRNA) molecules that are modified to be resistant to nuclease degradation, which inactivates a virus, and more specifically, hepatitis C virus (HCV). The invention also provides a method of using these modified RNA molecules to inactivate virus in mammalian cells and a method of making modified small interfering RNAs (siRNAs) using human Dicer. The invention provides modified RNA molecules that are modified to include a dsRNA or siRNA wherein one or more of the pyrimidines in the RNA molecule are modified to include 2′-Fluorine. The invention also provides dsRNA or siRNA in which all pyrimidines are modified to include a 2′-Fluorine. The invention provides that the 2′-Fluorine dsRNA or siRNA molecule is further modified to include a two base deoxynucleotide “TT” sequence at the 3′ end of the molecule. | 05-28-2015 |
20150148377 | Quinoline Derivatives - The invention relates to quinoline compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, W, U, Q, R | 05-28-2015 |
20150148374 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF - The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. | 05-28-2015 |
20150148349 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF - The present invention provides a compound of formula (I): a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. | 05-28-2015 |
20150148294 | Neuroendocrine Tumor Treatment - A method for treating endocrine tumors by administration of an mTOR inhibitor, optionally in combination with another drug. | 05-28-2015 |
20150141615 | ALDEHYDE ACETAL BASED PROCESSES FOR THE MANUFACTURE OF MACROCYCLIC DEPSIPEPTIDES AND NEW INTERMEDIATES - The invention relates to a method or process for the chemical manufacture of depsipeptides of the formula I employing an aldehyde acetal intermediate, | 05-21-2015 |
20150141474 | CYCLIC ETHER DGAT1 INHIBITORSCYCLIC ETHER DGAT1 INHIBITORS - The invention relates to compounds of formula (I): useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment. | 05-21-2015 |
20150141455 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF - The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. | 05-21-2015 |
20150141427 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 - The present invention relates to compounds of formula I: in which Y, Y | 05-21-2015 |
20150141354 | GLYCOSIDE DERIVATIVES AND USES THEREOF - This invention relates to compounds represented by formula (I): | 05-21-2015 |
20150139950 | ALISPORIVIR TO TREAT HEPATITIS C VIRUS INFECTION - The disclosure concerns the use of cyclophilin inhibitors in the treatment of chronic Hepatitis C virus infection. | 05-21-2015 |
20150134059 | DEFORMABLE ACCOMMODATIVE INTRAOCULAR LENS - A deformable accommodating intraocular lens (IOL) is disclosed, where the IOL comprises a diffractive kinoform-like grating pattern on one or both of the anterior or posterior surfaces of the deformable IOL. The capsular bag of the eye exerts a distorting force on the IOL, changing its power and allowing for accommodation. The focal length variation obtained by the change in curvature of the refractive surface of the IOL is enhanced by the kinoform-like diffractive grating pattern in combination with the traditional refractive surface. The focal length variation obtained by stretching and shrinking of the diffractive pattern adds considerable power variation independent of the refractive index of the material used to make the IOL. | 05-14-2015 |
20150133473 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS - The present invention provides a compound of formula (A): | 05-14-2015 |
20150126513 | 4-PIPERIDINYL COMPOUNDS FOR USE AS TANKYRASE INHIBITORS - The present invention provides for compounds of formula (I): | 05-07-2015 |
20150126492 | Complement Pathway Modulators and Uses Thereof - The present invention provides a compound of formula I a method for manufacturing the compounds of the invention, and its therapeutic uses as inhibitor of the complement alternative pathway and particularly as inhibitor of Factor B for the treatment of e.g. age-related macular degeneration and diabetic retinopathy. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition. | 05-07-2015 |
20150126490 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS - The present invention provides a compound of Formula (I) or a salt thereof; | 05-07-2015 |
20150126485 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 - The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the tyrosine kinase enzymatic activity of the Abelson protein (ABL1), the Abelson-related protein (ABL2) and related chimeric proteins, in particular BCR-ABL1. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers. | 05-07-2015 |
20150125857 | CANCER PATIENT SELECTION FOR ADMINISTRATION OF Wnt SIGNALING INHIBITORS USING RNF43 MUTATION STATUS - Disclosed are biomarkers, methods and assay for the identification of cancer patients who are predicted to benefit from the therapeutic administration of Wnt antagonist. The biomarkers include detection of RNF43 and ZNRF3 gene deletion, reduced RNF43 and ZNRF3 mRNA expression, reduced RNF43 and ZNRF3 protein expression, RNF43 and ZNRF3 inactivation mutation, phosphorylated LRP6, phophorylated Dishevelleds, and the expression of Frizzleds. These biomarkers can be associated with the better outcome for cancer patients treated with Wnt pathway inhibitors. | 05-07-2015 |
20150125453 | Monoclonal Antibodies and Methods of Use - This disclosure relates to immunogens and monoclonal antibodies useful in the identification and/or treatment of cancer cells, including those of the dog. In one example, chimeric anti-canine CD20 antibodies are provided. The antibodies can be used therapeutically to treat lymphoma in dogs. | 05-07-2015 |
20150119385 | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors - The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; | 04-30-2015 |